Brief: Vivoryon Shares Clinical Development Update Highlighting Progress Of N3pE-Amyloid-Targeting Small Molecule Varoglutamstat In Alzheimer’S Disease

Vivoryon Therapeutics NV

16/07/2023 08:14

July 16 (Reuters) - Vivoryon Therapeutics Nv  05Y.F :
    * VIVORYON THERAPEUTICS N.V.SHARES CLINICAL DEVELOPMENT
UPDATE
HIGHLIGHTING PROGRESS OF N3PE-AMYLOID-TARGETING SMALL MOLECULE
VAROGLUTAMSTAT IN ALZHEIMER’S DISEASE
    * VIVIAD PHASE 2B STUDY IN EUROPE ON TRACK FOR FINAL DATA
READOUT
Q1/2024
    * VIVA-MIND PHASE 2 STUDY IN U.S. STEADILY PROGRESSING,
RECRUITMENT INTO SECOND COHORTONGOING
    * COMMENCED PREPARATIONS FOR OPEN LABEL EXTENSION STUDY TO
PROVIDELONG-TERM TREATMENT OPTION TO PATIENTS AFTER COMPLETION
OF TREATMENT

Source text for Eikon:  ID:nGNE1Rbxmw 
Further company coverage:  05Y.F 

 ((Reuters.Briefs@thomsonreuters.com;))